Focus Partners Advisor Solutions LLC Purchases 2,518 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Focus Partners Advisor Solutions LLC boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 128.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 4,473 shares of the medical equipment provider’s stock after acquiring an additional 2,518 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Zimmer Biomet were worth $408,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZBH. Brighton Jones LLC bought a new stake in Zimmer Biomet during the 4th quarter worth approximately $204,000. Mirae Asset Global Investments Co. Ltd. raised its position in Zimmer Biomet by 12.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,941 shares of the medical equipment provider’s stock valued at $2,800,000 after buying an additional 2,785 shares during the last quarter. Amalgamated Bank raised its position in Zimmer Biomet by 0.9% in the 1st quarter. Amalgamated Bank now owns 38,667 shares of the medical equipment provider’s stock valued at $4,376,000 after buying an additional 348 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Zimmer Biomet by 2.5% in the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 23,236 shares of the medical equipment provider’s stock valued at $2,630,000 after buying an additional 557 shares during the last quarter. Finally, DAVENPORT & Co LLC raised its position in Zimmer Biomet by 11.1% in the 1st quarter. DAVENPORT & Co LLC now owns 38,953 shares of the medical equipment provider’s stock valued at $4,383,000 after buying an additional 3,893 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $99.55 on Friday. The stock has a fifty day simple moving average of $101.59 and a two-hundred day simple moving average of $97.62. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The firm has a market cap of $19.72 billion, a price-to-earnings ratio of 24.22, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. The company had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ZBH shares. Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. UBS Group increased their price target on Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research report on Friday, August 8th. BTIG Research upped their target price on Zimmer Biomet from $118.00 to $122.00 and gave the company a “buy” rating in a report on Monday, October 13th. Raymond James Financial upped their target price on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $111.94.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.